Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2019-04-16 Proxy Solicitation & In…
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2019-04-16 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the Annual Meeting of Stockholders of Moleculin Biotech, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, voting procedures, and other related governance matters. The document is not the actual Annual Report (10-K) or financial statements but is a solicitation of proxies for voting at the Annual Meeting. It contains governance-related content such as election of directors, amendments to the certificate of incorporation, and ratification of auditors. The document is lengthy (15,000 characters) and contains the full proxy statement text, not just an announcement or notice. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2019-04-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2019, by Moleculin Biotech, Inc. It announces a press release about entering an agreement for a clinical trial. The document is short (3655 characters) and primarily serves to announce the press release, which is attached as Exhibit 99.1. There are no financial statements or detailed financial data included. The document is a current report filing used to disclose material events and is not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-04-11 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-04-08 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC for the Annual Meeting of Stockholders of Moleculin Biotech, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, voting procedures, and other related governance matters. The document is not an actual annual report, earnings release, or financial statement, but rather a solicitation of proxies and information for shareholders to vote on corporate matters. The presence of the term 'Proxy Statement' and the detailed description of proposals such as election of directors, ratification of auditors, amendments to the certificate of incorporation, and stock issuance approvals confirm this is a Proxy Solicitation & Information Statement. The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or a brief notice. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2019-04-05 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under a shelf registration statement. It details an offering of 5,250,000 units consisting of common stock and warrants, including pricing, underwriting discounts, use of proceeds, risk factors, and legal matters. The document is a detailed disclosure related to a capital raising event, specifically a securities offering. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing unrelated to financing. The presence of terms like 'offering,' 'units,' 'warrants,' 'underwriting,' and 'prospectus' clearly indicates this is a Capital/Financing Update. The document length (15,000 characters) and detailed content confirm it is the actual offering document, not just an announcement of a report. Therefore, the correct classification is Capital/Financing Update (CAP).
2019-03-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.